BrainStorm Granted “Outperform” Rating by Murphy Analytics

A recently released report prepared by Murphy Analytics rated BrainStorm Cell Therapeutics (BCLI) as an “outperformer.” The report notes that the rating was “based on the Company’s progress to date and the magnitude of both the opportunity and need for new treatments for ALS and other neurodegenerative diseases.” BrainStorm is developing adult stem cell therapies for ALS and other neurodegenerative diseases. As noted by Dr. Clive Stevenson in ‘Stem Cells and ALS – Where are We Now?’ (ALS Association’s Fall 2008 ‘Research ALS Today’ periodical), stem cell based treatments are likely to be part of the answer.

Click here to read more.

Share this: